Trial Profile
A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Talimogene laherparepvec (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Adenocarcinoma; Rectal cancer
- Focus Adverse reactions
- 23 Mar 2022 Planned End Date changed from 30 Sep 2022 to 22 Mar 2023.
- 28 Jan 2022 Status changed from recruiting to active, no longer recruiting.
- 01 Oct 2021 Planned End Date changed from 30 Sep 2021 to 30 Sep 2022.